Actelion to axe 135 'mostly R&D' staff, PhII projects possibly up for grabs
This article was originally published in Scrip
Executive Summary
Actelion is cutting staff numbers by 135 globally, "the majority in R&D areas", as part of a cost cutting initiative first outlined in May this year. The Swiss firm currently employs around 800 R&D staff. Around 115 of the positions under threat are located in the company's headquarters in Allschwil, Switzerland.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.